Tresiba Regret, Stopping, and Restarting: What Real Patients and Clinicians Say

Why Patients Regret Starting Tresiba

Regret is not uniform. Patients who stop Tresiba within the first 90 days tend to cite different reasons than those who quit after six months or more. Understanding which category applies to you matters because it changes whether a restart makes sense and how to approach it.

The Cost Problem

Tresiba's list price sits around $530 per vial without insurance coverage, which places it among the more expensive basal insulins on the U.S. Market. The FDA approved a generic pathway for biosimilar insulins in 2021, but insulin degludec biosimilars have not yet reached wide U.S. Distribution as of mid-2025. Patients who had strong glycemic results but stopped for financial reasons are the clearest candidates for restart once coverage is secured or a patient assistance program is found. Novo Nordisk's Patient Assistance Program covers qualifying uninsured patients, and the FDA's biosimilar guidance outlines the regulatory framework for future lower-cost options.

Hypoglycemia Fear and Real Hypoglycemia

Some patients stop because of a hypoglycemic episode, or simply because they fear one is coming. This is clinically important to distinguish. A 2019 meta-analysis published in Diabetes Care covering 12 randomized trials (N=6,375) found that insulin degludec reduced confirmed nocturnal hypoglycemia by 25% and severe hypoglycemia by 47% compared with glargine U-100 [1]. That means Tresiba's pharmacology actually makes hypoglycemia less likely than with the most common alternative, not more. Patients who stopped because of a single low episode may have made a decision based on an outlier event rather than a pattern.

Weight Gain and Body Composition Concerns

Basal insulin therapy as a class carries a well-documented weight gain effect. In the BEGIN Once Long trial (N=1,030), patients on insulin degludec gained a mean of 1.6 kg over 52 weeks, compared with 1.5 kg on glargine U-100, showing the two are essentially equivalent on this metric [2]. Patients who stopped Tresiba hoping to avoid weight gain by switching to a different insulin are unlikely to see meaningful improvement unless they also add a GLP-1 receptor agonist or adjust diet and activity.

Injection Site Reactions and Practical Friction

A smaller group stops due to injection site discomfort, lipohypertrophy, or the daily routine itself. These are real barriers. Rotating injection sites across the abdomen, thigh, and upper arm, as recommended in the FDA-approved prescribing information for Tresiba [3], reduces lipohypertrophy risk substantially. Patients who stopped for this reason and who commit to proper rotation on restart tend to do better.

What the Clinical Evidence Actually Shows About Tresiba's Effectiveness

Before deciding whether to restart, patients deserve a clear-eyed view of what this drug does and does not do well, based on trial data rather than anecdote.

HbA1c Reduction Across Major Trials

The BEGIN trial program was the primary evidence base for Tresiba's FDA approval. BEGIN Once Long (N=1,030, 52 weeks, type 2 diabetes) showed insulin degludec reduced HbA1c by 0.79 percentage points from a baseline of 8.2%, compared with 0.96 percentage points for glargine U-100 [2]. The difference was within the pre-specified non-inferiority margin, meaning degludec performed comparably on glucose control while showing a hypoglycemia advantage. In BEGIN Basal-Bolus (N=1,006, type 1 diabetes), degludec produced a 0.40% HbA1c reduction, again non-inferior to glargine [4].

Fasting Plasma Glucose and Variability

One of Tresiba's most clinically meaningful attributes is its low day-to-day variability. A crossover pharmacodynamic study (N=54) published in Diabetes, Obesity and Metabolism measured within-subject variability of glucose-lowering effect and found insulin degludec had a coefficient of variation of 20%, compared with 82% for glargine U-100 [5]. Lower variability translates to more predictable glucose levels, which is exactly what patients who experienced erratic control on other basals often report as their reason for preferring Tresiba once they try it.

Type 1 vs. Type 2 Diabetes Outcomes

Patients with type 1 diabetes tend to report more pronounced subjective benefits from Tresiba's flat action profile, because they lack any endogenous insulin to buffer variability. The ADA's Standards of Medical Care in Diabetes (2024 edition) states that "ultra-long-acting insulin analogs (degludec, glargine U-300) have lower rates of hypoglycemia, particularly nocturnal hypoglycemia, compared to glargine U-100 and may be preferred for patients with problematic hypoglycemia" [6].

Real Patient Patterns: Reddit, Drugs.com, and Structured Survey Data

Patient-reported outcomes on platforms like Reddit (r/diabetes, r/diabetes_t1) and Drugs.com reflect a bimodal distribution. A substantial group rates Tresiba highly, particularly for stable overnight glucose and flexible dosing timing. A smaller but vocal group describes early regret.

What High Raters Describe

Patients who rate Tresiba positively most often cite three things: stable fasting glucose after the first two weeks of titration, fewer 3 a.m. Lows, and the ability to shift their injection time by a few hours without destabilizing their control. This flexibility is backed by pharmacokinetics. Because insulin degludec reaches its pharmacodynamic steady-state after 2 to 3 days of once-daily dosing, a single late or early injection has minimal impact on the following day's glucose [3].

What Low Raters Describe

Patients who rated Tresiba poorly most often describe a mismatch between expectation and reality during the first 7 to 14 days. Insulin degludec does not reach full steady-state effect until approximately 72 hours of consistent dosing. Patients who expected immediate tight control and saw higher-than-normal fasting readings in week one sometimes concluded the drug "wasn't working" and stopped before it had reached its effective plateau. This is a titration-phase phenomenon, not a drug failure.

Drugs.com Aggregate Rating Context

Drugs.com user ratings for Tresiba sit around 7.4 out of 10 based on several hundred reviews as of mid-2025. That places it above the platform average for basal insulins. Negative reviews cluster around cost, early titration confusion, and perceived weight gain, mirroring the trial data discussion above.

The Physiology of Stopping Tresiba: What Happens When You Quit

Stopping any basal insulin without a replacement plan creates an immediate gap in background insulin coverage. Because insulin degludec has a half-life of approximately 25 hours, its action winds down over roughly 2 to 3 days after the last dose [3]. For patients with type 2 diabetes who retain some beta-cell function, this period may pass without obvious hyperglycemia if diet is restricted and oral agents are in place. For patients with type 1 diabetes or insulin-deficient type 2 diabetes, stopping without replacement risks diabetic ketoacidosis within 24 to 48 hours.

Monitoring After Discontinuation

If stopping is planned (for example, during a hospitalization protocol that uses IV insulin instead), glucose checks every 4 to 6 hours are appropriate for the first 48 hours. The American Diabetes Association's inpatient glycemic management guidance recommends maintaining subcutaneous basal insulin even during minor illness unless oral intake is fully suspended [6]. Abrupt, unplanned stopping carries real risk.

Switching at Discontinuation

Many patients who "stop Tresiba" do not stop insulin entirely. They switch to a different basal, most often glargine U-100 (Lantus, Basaglar) or glargine U-300 (Toujeo) for cost or formulary reasons. The standard conversion is 1:1 unit-for-unit when switching between Tresiba and any glargine product, with a recommendation to check fasting glucose daily for the first week and titrate by 2 units every 3 days to target [3].

Restarting Tresiba After a Break: The Step-by-Step Protocol

Restarting insulin degludec after a gap of more than a few days requires a deliberate approach. The drug's long half-life means stacking doses during a restart can cause prolonged hypoglycemia.

Step 1: Recalculate Your Starting Dose

The standard clinical approach is to restart at 80% of the patient's prior total daily basal dose, then titrate upward. This conservative start accounts for any changes in insulin sensitivity that occurred during the off period, particularly if the break coincided with weight loss, illness recovery, or the addition of other glucose-lowering agents. The FDA label for Tresiba recommends a starting dose of 10 units once daily for insulin-naive patients, which provides a useful floor [3].

Step 2: Confirm Timing and Injection Site

Insulin degludec is injected subcutaneously once daily at any time of day, but the same time each day is preferred. Confirm that injection sites are rotated: abdomen, thigh, and upper arm are all approved locations. Do not inject into an area showing lipohypertrophy, as absorption from those sites is unpredictable.

Step 3: Titration Schedule

The manufacturer-recommended titration algorithm targets a fasting self-monitored blood glucose of 80 to 90 mg/dL. From the restart dose, increase by 2 units every 3 days if fasting glucose is consistently above 90 mg/dL. Do not increase during any period where fasting glucose is below 80 mg/dL or where unexplained hypoglycemia has occurred. Most patients reach their personal target dose within 4 to 8 weeks of consistent titration [3].

Step 4: Reassess Concurrent Medications

If you added or changed oral agents or GLP-1 receptor agonists during the Tresiba gap, your total insulin requirement will be different. GLP-1 receptor agonists in particular reduce the required basal insulin dose. A 2021 systematic review in The Lancet Diabetes and Endocrinology (N=6,016 across 16 trials) found that combining a GLP-1 agonist with basal insulin reduced HbA1c by an additional 0.44% and reduced hypoglycemia events compared with basal insulin titration alone [7]. Tell your prescriber about any medication changes before restarting.

Special Populations: Pregnancy, Renal Impairment, and Older Adults

Pregnancy

Tresiba is classified as FDA Pregnancy Category B based on animal data, but human safety data during pregnancy remain limited. The ACOG Practice Bulletin on diabetes in pregnancy recommends human insulin (NPH or regular) as the first-line agent for basal coverage in pregnant patients when possible, noting that analog data are less strong [8]. Patients who were on Tresiba before pregnancy and want to restart postpartum should discuss timing with their obstetric team, particularly if breastfeeding.

Renal Impairment

Insulin requirements generally decrease as renal function declines because the kidney contributes to insulin clearance. Patients with an estimated GFR below 30 mL/min/1.73 m² who restart Tresiba after a break should use a more conservative starting dose, perhaps 60 to 70% of prior dose rather than 80%, and monitor glucose more frequently in the first week. The FDA label notes that pharmacokinetic data in severe renal impairment are limited [3].

Older Adults

The American Geriatrics Society Beers Criteria (2023 update) does not list insulin degludec as a potentially inappropriate medication in older adults, but it flags sliding-scale insulin regimens specifically as high-risk [9]. Older patients restarting Tresiba benefit from a lower starting dose and a higher fasting glucose target (100 to 140 mg/dL is often appropriate) to reduce hypoglycemia risk, consistent with ADA guidance for older adults with multiple comorbidities [6].

Cost Reduction Strategies Before You Quit Again

Stopping for cost reasons is entirely understandable, but several options exist that patients often do not know about until after they have already stopped.

Novo Nordisk's patient assistance program (My$99Insulin) currently caps out-of-pocket costs at $99 per month for qualifying patients, including Tresiba, for those who meet income criteria. The program details are published on the manufacturer's website and are also referenced in FDA drug approval documentation [3]. GoodRx coupons for Tresiba at major retail pharmacies vary between $180 and $290 for a 5-pack of FlexTouch pens (300 units each) depending on pharmacy and region as of 2025. Patients should compare those prices to their plan's formulary cost before assuming their insurance is cheaper.

Switching to biosimilar glargine (Semglee, Rezvoglar) cuts cost significantly for some patients. These products are interchangeable with Lantus at the pharmacy level per FDA designation [10]. However, they are not interchangeable with Tresiba, because degludec and glargine are chemically distinct molecules with different pharmacodynamic profiles.

When Stopping Tresiba Is the Right Clinical Decision

Not every case of stopping Tresiba is regret-driven. Some stops are clinically appropriate.

Patients achieving HbA1c below 6.5% on a combination of Tresiba plus a GLP-1 receptor agonist, particularly those who have lost significant weight, may be candidates for a supervised trial off basal insulin entirely. A 2022 study in JAMA (N=316) found that patients with type 2 diabetes who underwent intensive GLP-1-based therapy and lost more than 10% body weight had a 51% rate of insulin discontinuation without glycemic deterioration at 12 months [11]. This is not applicable to type 1 diabetes, where endogenous insulin production is absent.

Patients experiencing recurrent severe hypoglycemia on Tresiba despite dose reduction, or those with adrenal insufficiency, pituitary disease, or active malignancy causing hypoglycemia, may also have a medically driven reason to stop. These situations require direct physician oversight, not self-management.